Antitumor activity of a novel survivin siRNA

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Breast cancer therapy resistance is often linked to antiapoptotic gene expression.
• Survivin, an antiapoptotic gene, is overexpressed in many human tumors, contributing to treatment failure.

Purpose of the Study:

• To evaluate a novel short interfering RNA (siRNA) designed to specifically inhibit survivin expression in breast cancer cells.
• To assess the impact of survivin knockdown on MCF-7 cell proliferation, cell cycle progression, and overall cellular behavior.

Main Methods:

• MCF-7 cells were treated with a novel survivin-targeted siRNA.
• Survivin mRNA and protein levels were quantified using real-time qRT-PCR and Western blot.
• Cellular morphology, cell cycle distribution, and proliferation were analyzed via fluorescence microscopy, flow cytometry, and MTT assay.

Main Results:

• The novel siRNA demonstrated efficient knockdown of survivin mRNA and protein expression.
• Survivin inhibition significantly reduced MCF-7 cell proliferation.
• The siRNA treatment arrested the cell cycle, particularly at the G2/M checkpoint.

Conclusions:

• The developed survivin-targeted siRNA effectively suppresses survivin expression in breast cancer cells.
• This targeted inhibition leads to decreased cell proliferation and cell cycle arrest.
• The findings suggest promising therapeutic potential for this siRNA in breast cancer treatment.